WEE1 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, the protein kinase inhibitor imatinib (Gleevec) was designed to treat chronic myelogenous leukemia (CML) based on knowledge of the causative molecular defect—translocation and dys-regulated BCR–ABL kinase.